These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 15852024

  • 1. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
    Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y, Tanosaki R, Mineishi S.
    Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
    [Abstract] [Full Text] [Related]

  • 2. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [Abstract] [Full Text] [Related]

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 4. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [Abstract] [Full Text] [Related]

  • 5. Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation.
    Forslöw U, Mattsson J, Gustafsson T, Remberger M.
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1214-21. PubMed ID: 21193056
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M, Mattsson J, Hassan Z, Karlsson N, LeBlanc K, Omazic B, Okas M, Sairafi D, Ringdén O.
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [Abstract] [Full Text] [Related]

  • 7. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Allogeneic myeloablative transplantation for patients aged 50 years and over.
    Yanada M, Emi N, Naoe T, Sakamaki H, Iseki T, Hirabayashi N, Karasuno T, Chiba S, Atsuta Y, Hamajima N, Takahashi S, Kato S.
    Bone Marrow Transplant; 2004 Jul; 34(1):29-35. PubMed ID: 15156161
    [Abstract] [Full Text] [Related]

  • 11. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.
    Kersting S, Hené RJ, Koomans HA, Verdonck LF.
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1169-75. PubMed ID: 17889353
    [Abstract] [Full Text] [Related]

  • 12. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children.
    Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M, Yoshida N, Watanabe N, Kudo K, Yoshimi A, Kojima S.
    Bone Marrow Transplant; 2009 Sep; 44(5):303-8. PubMed ID: 19349954
    [Abstract] [Full Text] [Related]

  • 13. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?
    Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW.
    Bone Marrow Transplant; 2013 Sep; 48(9):1224-9. PubMed ID: 23435515
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 15. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
    Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.
    Bone Marrow Transplant; 2005 Nov; 36(10):867-72. PubMed ID: 16113659
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D.
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.